Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones
Lower Ureteric Stones, Medical Expulsive Therapy, Tadalafil
About this trial
This is an interventional treatment trial for Lower Ureteric Stones
Eligibility Criteria
Inclusion Criteria: 168 patients aged >18 years old. Both sexes. Diagnosed with lower ureteric stone from 5mm to 10mm in size. Exclusion Criteria: Patients with multiple or bilateral ureteric stones single kidney or impairment of renal function Urinary tract infection (UTI) Marked hydronephrosis Patients presenting with severe intractable pain and requiring emergency intervention Any urologic anomalies or history of ureteral surgery Pregnancy Pediatric populations Ischemic heart disease Congestive cardiac failure Complicated hypertension Patients on concomitant treatment with nitrates or calcium channel blockers.
Sites / Locations
- Benha University Hospitals
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Placebo Comparator
Experimental
Experimental
Experimental
Placebo group
Silodosin group
Tadalafil group
Silodosin and Tadalafil
Patients in this group will receive placebo treatment once daily.
Patients will receive Silodosin 8 mg once daily.
Patients will receive Tadalafil 5 mg once daily.
Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.